Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript
Omnicell, Inc. (OMCL) Q4 2025 Earnings Call Transcript
Omnicell (OMCL) Q4 Earnings Lag Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.4 per share, missing the Zacks Consensus Estimate of $0.47 per share. This compares to earnings of $0.6 per share a year ago.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Earnings Preview: Omnicell (OMCL) Q4 Earnings Expected to Decline
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Omnicell (OMCL) Rating Upgrade to Buy
Omnicell (OMCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Reasons to Add Omnicell Stock to Your Portfolio Right Now
OMCL's expanding SaaS pipeline, global push and solid solvency highlight growth potential despite rising competition.
Wall Street Analysts Think Omnicell (OMCL) Could Surge 30.93%: Read This Before Placing a Bet
The consensus price target hints at a 30.9% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Wall Street Analysts Believe Omnicell (OMCL) Could Rally 34.53%: Here's is How to Trade
The consensus price target hints at a 34.5% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
